Eli Lilly and Company (LLY) income statement
NYSE · Healthcare · Drug Manufacturers - General · 50,000 employees · CEO David A. Ricks
- Price
- $1,417.54 +3.19%
- Market cap
- $1.33T
- Enterprise value
- $1.38T
- Last report
- Q3 '26 filed 2026-10-29
- Next report
- 2027-02-03 EPS est. $11.07
Eli Lilly and Company (LLY) reported revenue of $24.4B for Q3 '26 (+38.6% year on year), operating income of $8.61B (35.3% of revenue) and net income of $6.45B. Over the last four quarters revenue was $86.5B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.35B | $8.77B | $11.3B | $11.4B | $13.5B | $12.7B | $15.6B | $17.6B | $19.3B | $19.8B | $23B | $24.4B | |
| Cost of revenue | $1.79B | $1.67B | $2.17B | $2.17B | $2.4B | $2.23B | $2.45B | $3.01B | $3.37B | $3.58B | $3.27B | $3.93B | |
| Gross profit | $7.57B | $7.09B | $9.13B | $9.27B | $11.1B | $10.5B | $13.1B | $14.6B | $15.9B | $16.2B | $19.7B | $20.5B | |
| Research & development | $2.56B | $2.52B | $2.71B | $2.73B | $3.02B | $2.73B | $3.34B | $3.47B | $3.8B | $3.51B | $3.82B | $4.25B | |
| Sales & marketing | $0 | $0 | $0 | $0 | $0 | -$800K | $0 | $0 | $0 | $0 | $0 | $0 | |
| General & administrative | $1.81B | $1.84B | $2B | $2.1B | $2.42B | $2.47B | $2.75B | $2.74B | $0 | $0 | $0 | $3.13B | |
| Other operating expenses | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $4.48B | |
| Operating expenses | $4.37B | $4.36B | $4.71B | $4.83B | $5.45B | $5.2B | $6.09B | $6.21B | $6.93B | $6.44B | $7.25B | $11.9B | |
| Operating income | $3.19B | $2.74B | $4.42B | $4.43B | $5.68B | $5.3B | $7.02B | $8.39B | $8.99B | $9.78B | $12.5B | $8.61B | |
| Interest income | $44.5M | $45.8M | $37.3M | $47.8M | $44.3M | $48.3M | $40M | $65M | $0 | $0 | $0 | $0 | |
| Interest expense | $138M | $180M | $184M | $193M | $225M | $244M | $249M | $180M | $123M | $332M | $345M | $378M | |
| Other non-operating income (gains on investments, FX ...) | $546M | $19.9M | $718M | $2.65B | $419M | $0 | $0 | $974M | -$2.57B | $0 | $0 | -$176M | |
| Total non-operating income | -$684M | -$200M | -$901M | -$2.85B | -$643M | -$1.85B | -$244M | -$1.15B | -$721M | -$928M | -$3.21B | -$202M | |
| Income before tax | $2.51B | $2.54B | $3.52B | $1.59B | $5.04B | $3.46B | $6.78B | $7.23B | $8.27B | $8.85B | $9.25B | $8.41B | |
| Income tax | $319M | $293M | $550M | $618M | $629M | $697M | $1.12B | $1.65B | $1.63B | $1.45B | $2.15B | $1.96B | |
| Net income | $2.19B | $2.24B | $2.97B | $970M | $4.41B | $2.76B | $5.66B | $5.58B | $6.64B | $7.4B | $7.1B | $6.45B | |
| EPS (basic) | $2.43 | $2.49 | $3.29 | $1.08 | $4.91 | $3.07 | $6.30 | $6.23 | $7.42 | $8.28 | $7.96 | $7.23 | |
| EPS (diluted) | $2.42 | $2.48 | $3.28 | $1.07 | $4.88 | $3.06 | $6.29 | $6.21 | $7.39 | $8.26 | $7.94 | $7.22 | |
| Shares (basic, weighted) | 899M | 901M | 901M | 901M | 898M | 898M | 898M | 897M | 898M | 895M | 892M | 892M | |
| Shares (diluted, weighted) | 904M | 904M | 904M | 905M | 903M | 901M | 900M | 899M | 898M | 896M | 894M | 893M | |
| Depreciation & amortization | $388M | $401M | $414M | $467M | $485M | $463M | $478M | $470M | $586M | $509M | $534M | $545M | |
| EBITDA | $3.03B | $3.12B | $4.12B | $2.25B | $5.75B | $5.77B | $7.5B | $7.88B | $12.1B | $10.3B | $13B | $9.33B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.2B | $20B | $21.5B | $22.3B | $24.5B | $28.3B | $28.5B | $34.1B | $45B | $65.2B | |
| Cost of revenue | $5.71B | $4.45B | $4.68B | $4.72B | $5.48B | $7.31B | $6.63B | $7.08B | $8.42B | $11.1B | |
| Gross profit | $15.5B | $15.5B | $16.8B | $17.6B | $19.1B | $21B | $21.9B | $27B | $36.6B | $54.1B | |
| Research & development | $5.31B | $5.1B | $5.05B | $5.6B | $5.98B | $6.93B | $7.19B | $9.31B | $11B | $13.3B | |
| Sales & marketing | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $200K | $0 | |
| General & administrative | $6.33B | $6.18B | $5.73B | $6B | $5.87B | $6.14B | $6.07B | $6.94B | $8.59B | $0 | |
| Operating expenses | $11.6B | $11.3B | $10.8B | $11.6B | $11.8B | $13.1B | $13.3B | $16.3B | $19.6B | $24.4B | |
| Operating income | $3.87B | $4.25B | $6.03B | $6B | $7.21B | $7.93B | $8.65B | $10.8B | $17B | $29.7B | |
| Interest income | $109M | $166M | $159M | $80.4M | $33M | $25.4M | $62.8M | $174M | $175M | $153M | |
| Interest expense | $185M | $225M | $243M | $401M | $360M | $340M | $332M | $486M | $781M | $795M | |
| Other non-operating income (gains on investments, FX ...) | $312M | $1.72B | $2.1B | $333M | -$379M | $1.44B | $1.52B | $3.75B | $0 | $0 | |
| Total non-operating income | -$497M | -$1.95B | -$2.35B | -$734M | $19.1M | -$1.78B | -$1.85B | -$4.23B | -$4.36B | -$3.97B | |
| Income before tax | $3.37B | $2.3B | $3.68B | $5.27B | $7.23B | $6.16B | $6.81B | $6.55B | $12.7B | $25.7B | |
| Income tax | $636M | $2.39B | $530M | $628M | $1.04B | $574M | $562M | $1.31B | $2.09B | $5.09B | |
| Net income | $2.74B | -$204M | $3.23B | $8.32B | $6.19B | $5.58B | $6.24B | $5.24B | $10.6B | $20.6B | |
| EPS (basic) | $2.49 | -$0.19 | $3.14 | $8.69 | $6.47 | $5.85 | $6.57 | $5.83 | $11.76 | $23.07 | |
| EPS (diluted) | $2.49 | -$0.19 | $3.13 | $8.69 | $6.47 | $5.85 | $6.57 | $5.80 | $11.71 | $22.95 | |
| Shares (basic, weighted) | 1.1B | 1.05B | 1.03B | 958M | 957M | 954M | 950M | 899M | 901M | 898M | |
| Shares (diluted, weighted) | 1.1B | 1.05B | 1.03B | 958M | 957M | 954M | 950M | 903M | 904M | 898M | |
| Depreciation & amortization | $1.5B | $1.57B | $1.61B | $1.23B | $1.32B | $1.55B | $1.52B | $1.53B | $1.77B | $2B | |
| EBITDA | $5.06B | $4.1B | $5.53B | $6.9B | $8.91B | $8.04B | $8.66B | $8.57B | $18.8B | $31.7B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-01